61Cu-NODAGA-LM3 PET/CT for the Detection of Neuroendocrine Tumors (COPPER PET in NET)

计划入组 27 人 · 首次发布于 2024 年 6 月 12 日

A Phase I Trial of 61Cu-NODAGA-PSMA for Patients with Prostate Cancer

计划入组 8 人 · 首次发布于 2024 年 12 月 16 日

Comparison of Al18F-NOTA-LM3 With 68Ga-DOTATATE and 68Ga-NODAGA-LM3 PET/CT in Patients With Well-differentiated Neuroendocrine Tumors

计划入组 80 人 · 首次发布于 2023 年 9 月 28 日

61Cu-NODAGA-LM3

64Cu-NODAGA-LM3

68Ga-NODAGA-LM3

CU CHEMIE UETIKON GmbH

Germany

CU Anschutz Medical Campus

United States

CHULALONGKORN UNIVERSITY

Thailand

NUCLIDIUM's Copper-Based PET Tracer Shows Promise in Phase I/II Trial for Neuroendocrine Tumor Detection

NUCLIDIUM's Copper-Based Radiotracer Shows Enhanced Imaging Performance in First Prostate Cancer Patient

CU Cancer Center's Innovative Approaches Lead to Higher Survival Rates